Bal Pharma Limited (NSE:BALPHARMA)

Market Cap	1.15B
Revenue (ttm)	2.95B
Net Income (ttm)	68.25M
Shares Out	n/a
EPS (ttm)	4.29
PE Ratio	16.80
Forward PE	n/a
Dividend	1.20 (1.62%)
Ex-Dividend Date	Sep 18, 2025

Volume	9,286
Average Volume	7,244
Open	73.20
Previous Close	73.34
Day's Range	71.54 - 73.20
52-Week Range	70.05 - 132.00
Beta	0.20
RSI	38.00
Earnings Date	Feb 10, 2026

About Bal Pharma

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic p...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 986
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BALPHARMA

Financial Performance

In 2024, Bal Pharma's revenue was 3.03 billion, a decrease of -10.65% compared to the previous year's 3.39 billion. Earnings were 72.15 million, a decrease of -2.39%.